Xencor to Participate at Upcoming Investor Conferences Read more about Xencor to Participate at Upcoming Investor Conferences
Xencor Reports Third Quarter 2024 Financial Results Read more about Xencor Reports Third Quarter 2024 Financial Results
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease Read more about Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases Read more about Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
Xencor Announces Upcoming Change to Board of Directors Read more about Xencor Announces Upcoming Change to Board of Directors
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Read more about Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Xencor Announces Pricing of $175 Million Public Offering of Common Stock Read more about Xencor Announces Pricing of $175 Million Public Offering of Common Stock
Xencor Announces Proposed Public Offering of Common Stock Read more about Xencor Announces Proposed Public Offering of Common Stock
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs Read more about Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 Read more about Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
